Efficacy and Safety of Baricitinib for Active Rheumatoid Arthritis in Patients With an Inadequate Response to Conventional Synthetic or Biological Disease‑modifying Anti‑rheumatic Drugs: A Meta‑analysis of Randomized Controlled Trials

Experimental and Therapeutic Medicine - Greece
doi 10.3892/etm.2018.6495
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Safety, Cost and Effectiveness Issues With Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1999English

Efficacy and Safety of Sirukumab in Japanese Patients With Moderate to Severe Rheumatoid Arthritis Inadequately Controlled by Disease Modifying Anti-Rheumatic Drugs: Subgroup Analysis of a Phase 3 Study

Modern Rheumatology
MedicineRheumatology
2018English

Pms3 - Infliximab for Disease-Modifying Anti-Rheumatic Drug-Naive Rheumatoid Arthritis Patients: Systematic Review and Descriptive Analysis of Publications of Randomized Controlled Trials

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients With Rheumatoid Arthritis?

Neurotherapeutics
NeurologyPharmacology
2019English

Safety of Abatacept Compared With Other Biologic and Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Data From an Observational Study

Arthritis Research & Therapy
2019English

OP0281-HPR Preferences of Patients With Rheumatoid Arthritis Regarding Disease Modifying Anti-Rheumatic Drugs: A Discrete Choice Experiment

2018English

AB0490 Evaluation of Inhibitory Factor of Radiographic Progression by Iguratimod Add-On Therapy in Rheumatoid Arthritis Patients With Inadequate Responses to Disease-Modifying Anti-Rheumatic Drugs

2018English

Biological Targets in the Treatment of Rheumatoid Arthritis: A Comprehensive Review of Current and In-Development Biological Disease Modifying Anti-Rheumatic Drugs

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Ixekizumab Is Efficacious When Used Alone or When Added to Conventional Synthetic Disease-Modifying Antirheumatic Drugs (cDMARDs) in Patients With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors

RMD Open
RheumatologyAllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy